extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
+
+### Additional Evidence (extend)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
+
+FLOW trial provides strongest economic counterargument to inflationary thesis: preventing dialysis ($90K+/year) through 1.16 mL/min/1.73m2 slower eGFR decline creates immediate cost offset in CKD population. This is the one indication where downstream savings clearly exceed drug cost within budget scoring windows.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -34,7 +34,7 @@ For value-based care models and capitated payers, this multi-organ protection cr
 ### Additional Evidence (confirm)
 *Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
 
-FLOW trial demonstrated simultaneous benefits: 24% kidney disease reduction, 29% cardiovascular death reduction, and 18% reduction in major cardiovascular events in a single trial population. The cardiovascular death benefit emerged in a kidney-focused trial, demonstrating cross-organ protection. Separate analysis showed additive benefits when combined with SGLT2 inhibitors.
+FLOW trial demonstrated simultaneous kidney protection (24% risk reduction), cardiovascular death reduction (29%), and major cardiovascular event reduction (18%) in a single trial population, with additive benefits when combined with SGLT2 inhibitors per Nature Medicine analysis.
 
 ---
 

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -32,7 +32,7 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 ### Additional Evidence (confirm)
 *Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
 
-FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), 29% reduction in cardiovascular death (HR 0.71), and slowed eGFR decline by 1.16 mL/min/1.73m2 annually. Trial stopped early for efficacy. FDA expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM.
+FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), 29% reduction in cardiovascular death (HR 0.71), and slowed eGFR decline by 1.16 mL/min/1.73m2 annually. Trial stopped early for efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD.
 
 ---
 

entities/internet-finance/metadao.md

@@ -65,6 +65,8 @@ The futarchy governance protocol on Solana. Implements decision markets through
 - **2024-01-24** — Proposed AMM program to replace CLOB markets, addressing liquidity fragmentation and state rent costs (Proposal CF9QUBS251FnNGZHLJ4WbB2CVRi5BtqJbCqMi47NX1PG)
 - **2024-01-29** — AMM proposal passed with 400 META on approval and 800 META on completion budget
 - **2024-08-31** — Passed proposal to enter services agreement with Organization Technology LLC, creating US entity vehicle for paying contributors with $1.378M annualized burn rate. Entity owns no IP (all owned by MetaDAO LLC) and cannot encumber MetaDAO LLC. Agreement cancellable with 30-day notice or immediately for material breach.
+- **2024-01-29** — AMM program proposal completed and migration executed, transitioning MetaDAO from CLOB to AMM-based futarchy markets with liquidity-weighted price over time as decision metric.
+- **2024-03-19** — Colosseum proposes $250,000 OTC acquisition of META with TWAP-based pricing (floor $850, ceiling $1,200), 20% immediate unlock and 80% vested over 12 months; proposal passes 2024-03-24
 ## Key Decisions
 | Date | Proposal | Proposer | Category | Outcome |
 |------|----------|----------|----------|---------|

inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md

@@ -12,7 +12,7 @@ priority: high
 tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection]
 processed_by: vida
 processed_date: 2026-03-16
-enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
+enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
@@ -48,5 +48,6 @@ EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for
 - FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease
 - Median follow-up was 3.4 years before early stopping
 - Trial was stopped at prespecified interim analysis due to efficacy
-- FDA expanded semaglutide (Ozempic) indications to include T2D patients with CKD
-- Separate analysis in Nature Medicine showed additive benefits with SGLT2 inhibitors
+- Annual eGFR slope difference was 1.16 mL/min/1.73m2
+- Dialysis costs approximately $90,000+ per year per patient in the US
+- Separate Nature Medicine analysis showed additive benefits with SGLT2 inhibitors